One of the biggest movers on the market today has been the Resapp Health Ltd (ASX: RAP) share price.
At the time of writing the embattled digital healthcare solutions company's shares are up a massive 24% to 8.3 cents.
Why have its shares jumped?
In August the ResApp share price fell an incredible 77% in a single day after the company released negative results relating to its Smartcough C study.
According to that release, analysis of the study data revealed issues in the quality of cough recordings and that many patients were treated before their coughs were recorded.
As a result, the predefined endpoints for positive percent agreement and negative percent agreement with clinical diagnosis were unlikely to be met.
However, this morning the company advised that further analysis of the data and reviews with principal investigators have confirmed that the study was not a representative evaluation of its ResAppDx app due to a number of issues during execution and adjudication.
In light of this, it appears as though some investors are betting on better results second time around when the company restarts the study in the U.S. winter.
Should you invest?
Whilst it does appear as though the first study was a complete shambles and the ResAppDx app was not given a chance to prove its worth, I would suggest investors stay clear of the company for the time being.
All being well the app will deliver on its goals next time around, but if it doesn't then the ResApp share price is almost certain to come crashing down again.
